Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia
Abstract Background The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread. Main body Although the prod...
Main Author: | Heba K. Nabih |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-02-01
|
Series: | Bulletin of the National Research Centre |
Subjects: | |
Online Access: | https://doi.org/10.1186/s42269-021-00502-4 |
Similar Items
-
Convalescent Plasma: An Old Trick for the Treatment of COVID-19
by: Reza Jafari, et al.
Published: (2020-07-01) -
Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature
by: Sunha Choi, et al.
Published: (2021-09-01) -
Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19
by: Mahima Lall, et al.
Published: (2021-01-01) -
Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions
by: Jayanth Seshan, et al.
Published: (2020-09-01) -
Convalescent (Immune) Plasma Therapy with all Aspects: Yesterday, Today and COVID-19
by: Öner Özdemir, et al.
Published: (2020-06-01)